ArticleScientific reports2025
Immune signature and pathways investigation of adrenal gland diffuse large B-cell lymphoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diffuse large B-cell lymphoma (DLBCL) accounts for approximately 30-40% of all non-Hodgkin lymphoma cases. Organs located DLBCL such as lymph node, stomach, gastrointestinal tract, or skin were reported. However, the adrenal gland DLBCL was not been well explored. We performed RNA sequencing of ten DLBCL samples from adrenal gland, integrated analyzed DLBCL RNA data from multiple organs, defined the new subtypes of adrenal gland DLBCL and explored their molecular signatures. The special expression pattern and microenvironment immunology scores of adrenal glands DLBCL were observed when compared with other organs. Natural killer T cells was predicted to significantly enrichment in adrenal gland DLBCL, canonical cancer pathways such as programmed death protein 1 signaling pathways, tumor necrosis factor signaling pathways and peptide antigen binding pathways were found to be correlated with adrenal gland DLBCL. Further analysis defined two distant adrenal gland DLBCL sub-type by RNA expression pattern. Our study revealed the special expression, defined the molecular subtype of adrenal gland DLBCL. These results expanded the organ related DLBCL data, provided the new knowledge of adrenal gland DLBCL expression profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.